Intersect Ent Inc represents a strong commitment to advancing patient care in the field of ear, nose, and throat (ENT) disorders. The company focuses on developing innovative treatments that improve the quality of life for individuals suffering from chronic sinusitis. Intersect Ent Inc integrates cutting-edge technologies and research to provide minimally invasive and clinically proven solutions. With a patient-centric approach, the company strives to enhance patient outcomes and experiences. By maintaining a culture of excellence, collaboration, and integrity, Intersect Ent Inc continually seeks to revolutionize the ENT industry and set new standards for medical innovation.

Intersect Ent Inc is primarily present in the United States.

Intersect Ent Inc has achieved several significant milestones. Notably, the company developed and commercialized Propel and Propel Mini, innovative steroid-releasing sinus implants, which revolutionized the treatment of chronic sinusitis. Intersect Ent Inc also gained FDA approval for Propel Contour, a next-generation sinus implant with improved delivery capability. Additionally, the company has successfully expanded its product portfolio and worldwide reach, securing partnerships and distribution agreements with leading global healthcare companies. Through continuous innovation and dedication, Intersect Ent Inc continues to improve the lives of patients suffering from chronic sinusitis while solidifying its position as a market leader in the field.

Intersect Ent Inc. is a renowned medical technology company specializing in the development of innovative therapies for chronic sinusitis patients. Founded in 2003, Intersect Ent has become a leader in improving the quality of life for people suffering from sinus-related illnesses. The company's groundbreaking approach involves the use of localized drug delivery systems to provide effective and long-lasting relief to patients. Intersect Ent has consistently pushed the boundaries of medical advancements and has earned recognition for its revolutionary technology. With a strong commitment to patient care, the company continues to strive for excellence in addressing the needs of those affected by chronic sinusitis.

The main competitors of Intersect Ent Inc in the market are Medtronic, Johnson & Johnson, and Olympus Corporation.

Intersect Ent Inc is primarily active in the healthcare industry, specifically in the field of medical devices. They specialize in the development and manufacturing of innovative therapies for ear, nose, and throat conditions. With a strong focus on providing minimally invasive solutions, Intersect Ent Inc aims to enhance patients' quality of life and improve treatment outcomes. The company's dedication to advancing medical innovations has established them as a trusted player in the healthcare sector.

Intersect Ent Inc. operates under a business model focused on developing and commercializing innovative therapies for patients with ear, nose, and throat (ENT) conditions. The company specializes in designing and delivering localized therapies directly to the site of a patient's disease. This enables precise, effective treatment while reducing the need for invasive surgeries. Intersect Ent Inc. aims to provide long-term solutions for patients suffering from chronic sinusitis and related conditions. Their business model revolves around leveraging advanced technology and medical expertise to improve the quality of life for individuals affected by ENT disorders.

Το Intersect Ent P/E είναι -21,44.

Το KUV της εταιρείας Intersect Ent είναι 4,84.

Το AlleAktien Qualitätsscore για το Intersect Ent είναι 4/10.

Ο κύκλος εργασιών του αναμενόμενη Intersect Ent είναι 194,10 Εκ. USD.

Το αναμενόμενη Intersect Ent κέρδος είναι -43,81 Εκ. USD.

Intersect Ent Inc is an American company that manufactures and distributes medical devices for the treatment of ear, nose, and throat problems. The company was founded in 2003 and is headquartered in Menlo Park, California. It specializes in two main areas: the ear and the otolaryngology (ENT) field. In the ear area, Intersect Ent Inc offers innovative products to treat patients with chronic sinusitis and rhinosinus polyposis. In the ENT field, the company offers a wide range of products to treat conditions such as sinusitis, allergic rhinitis, and nasal congestion. The company is known for its innovative technologies that improve methods for treating ear, nose, and throat problems. It operates in North America, Europe, and Asia and collaborates with partner companies and distributors to expand its market share. The company also strives to collaborate with medical professionals, research institutions, and industry organizations to improve and develop its products and services. Overall, Intersect Ent Inc is a growing player in the ENT medicine market and is committed to improving the quality of life of patients by offering innovative solutions that simplify the treatment of ear, nose, and throat problems.

Η Intersect Ent καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Intersect Ent αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Intersect Ent είναι US46071F1030.

Το WKN της Intersect Ent είναι A117WV.

Ο τίκερ της Intersect Ent είναι XENT.

Κατά τους τελευταίους 12 μήνες η Intersect Ent κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Intersect Ent προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Intersect Ent ανέρχεται σήμερα στο .

Intersect Ent πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Intersect Ent πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Intersect Ent ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Intersect Ent από την 10/10/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 10/10/2024.

Η τελευταία μερίσματος έγινε στις 10/10/2024.

Το έτος 2023, η Intersect Ent διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Intersect Ent καταβάλλονται σε USD.